Abstract

The voltage-gated sodium (NaV) channel NaV1.7 has been identified as a potential novel analgesic target due to its involvement in human pain syndromes. However, clinically available NaV channel blocking drugs are not selective among the nine NaV channel subtypes, NaV1.1-NaV1.9. Moreover, the two currently known classes of NaV1.7 subtype-selective inhibitors (aryl- and acylsulfonamides) have undesirable characteristics that may limit their development. To this point understanding of the structure-activity relationships of the acylsulfonamide class of NaV1.7 inhibitors, exemplified by the clinical development candidate GDC-0310, has been based solely on a single co-crystal structure of an arylsulfonamide inhibitor bound to voltage-sensing domain 4 (VSD4). To advance inhibitor design targeting the NaV1.7 channel, we pursued high-resolution ligand-bound NaV1.7-VSD4 structures using cryogenic electron microscopy (cryo-EM). Here, we report that GDC-0310 engages the NaV1.7-VSD4 through an unexpected binding mode orthogonal to the arylsulfonamide inhibitor class binding pose, which identifies a previously unknown ligand binding site in NaV channels. This finding enabled the design of a novel hybrid inhibitor series that bridges the aryl- and acylsulfonamide binding pockets and allows for the generation of molecules with substantially differentiated structures and properties. Overall, our study highlights the power of cryo-EM methods to pursue challenging drug targets using iterative and high-resolution structure-guided inhibitor design This work also underscores an important role of the membrane bilayer in the optimization of selective NaV channel modulators targeting VSD4.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. The NaV1.7-NaVPas/GNE-3565 coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0R and EMDB entry ID EMD-28778, respectively. The NaV1.7-NaVPas/GDC-0310 coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0Q and EMDB entry ID EMD-28777, respectively. The NaV1.7-NaVPas bound to the hybrid molecule 2 (GNE-9296) coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0S and EMDB entry ID EMD-28779, respectively. The NaV1.7-NaVPas bound to the hybrid molecule 4 (GNE-1305) coordinates and cryo-EM maps were deposited in the PDB entry ID 8F0P and EMDB entry ID EMD-28776, respectively.

Article and author information

Author details

  1. Marc Kschonsak

    Structural Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  2. Christine C Jao

    Structural Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  3. Christopher P Arthur

    Structural Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  4. Alexis L Rohou

    Structural Biology, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  5. Philippe Bergeron

    Discovery Chemistry, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  6. Daniel F Ortwine

    Discovery Chemistry, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  7. Steven J McKerrall

    Discovery Chemistry, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  8. David H Hackos

    Neuroscience, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  9. Lunbin Deng

    Neuroscience, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  10. Jun Chen

    Biochemical and Cellular Pharmacology, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  11. Tianbo Li

    Biochemical and Cellular Pharmacology, Genentech, Inc, South San Francisco, United States
    Competing interests
    Tianbo Li, Genentech employee.
  12. Peter S Dragovich

    Discovery Chemistry, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  13. Matthew Volgraf

    Discovery Chemistry, Genentech, Inc, South San Francsico, United States
    Competing interests
    No competing interests declared.
  14. Matthew R Wright

    Drug Metabolism and Pharmacokinetics, Genentech, Inc, South San Francisco, United States
    Competing interests
    No competing interests declared.
  15. Jian Payandeh

    Structural Biology, Genentech, Inc, South San Francisco, United States
    For correspondence
    jpayandeh@exelixis.com
    Competing interests
    No competing interests declared.
  16. Claudio Ciferri

    Structural Biology, Genentech, Inc, South San Francisco, United States
    For correspondence
    ciferri.claudio@gene.com
    Competing interests
    Claudio Ciferri, MK, CCJ, ALR, DFO, DHH, LD, JC, PSD, MW, CC and JCT are Genentech employees. All authors declare no competing financial interest..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0804-2411
  17. John C Tellis

    Discovery Chemistry, Genentech, Inc, South San Francisco, United States
    For correspondence
    tellis.john@gene.com
    Competing interests
    No competing interests declared.

Funding

Genentech

  • Marc Kschonsak
  • Christine C Jao
  • Christopher P Arthur
  • Alexis L Rohou
  • Philippe Bergeron
  • Daniel F Ortwine
  • Steven J McKerrall
  • David H Hackos
  • Lunbin Deng
  • Jun Chen
  • Tianbo Li
  • Matthew Volgraf
  • Matthew R Wright
  • Jian Payandeh
  • Claudio Ciferri
  • John C Tellis

N/A

Copyright

© 2023, Kschonsak et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,099
    views
  • 627
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marc Kschonsak
  2. Christine C Jao
  3. Christopher P Arthur
  4. Alexis L Rohou
  5. Philippe Bergeron
  6. Daniel F Ortwine
  7. Steven J McKerrall
  8. David H Hackos
  9. Lunbin Deng
  10. Jun Chen
  11. Tianbo Li
  12. Peter S Dragovich
  13. Matthew Volgraf
  14. Matthew R Wright
  15. Jian Payandeh
  16. Claudio Ciferri
  17. John C Tellis
(2023)
Cryo-EM reveals an unprecedented binding site for NaV1.7 inhibitors enabling rational design of potent hybrid inhibitors
eLife 12:e84151.
https://doi.org/10.7554/eLife.84151

Share this article

https://doi.org/10.7554/eLife.84151

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Assmaa Elsheikh, Camden M Driggers ... Show-Ling Shyng
    Research Article

    Pancreatic KATP channel trafficking defects underlie congenital hyperinsulinism (CHI) cases unresponsive to the KATP channel opener diazoxide, the mainstay medical therapy for CHI. Current clinically used KATP channel inhibitors have been shown to act as pharmacochaperones and restore surface expression of trafficking mutants; however, their therapeutic utility for KATP trafficking-impaired CHI is hindered by high affinity binding, which limits functional recovery of rescued channels. Recent structural studies of KATP channels employing cryo-electron microscopy (cryoEM) have revealed a promiscuous pocket where several known KATP pharmacochaperones bind. The structural knowledge provides a framework for discovering KATP channel pharmacochaperones with desired reversible inhibitory effects to permit functional recovery of rescued channels. Using an AI-based virtual screening technology AtomNet followed by functional validation, we identified a novel compound, termed Aekatperone, which exhibits chaperoning effects on KATP channel trafficking mutations. Aekatperone reversibly inhibits KATP channel activity with a half-maximal inhibitory concentration (IC50) ~9 μM. Mutant channels rescued to the cell surface by Aekatperone showed functional recovery upon washout of the compound. CryoEM structure of KATP bound to Aekatperone revealed distinct binding features compared to known high affinity inhibitor pharmacochaperones. Our findings unveil a KATP pharmacochaperone enabling functional recovery of rescued channels as a promising therapeutic for CHI caused by KATP trafficking defects.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Andrew P Latham, Longchen Zhu ... Bin Zhang
    Research Article

    The phase separation of intrinsically disordered proteins is emerging as an important mechanism for cellular organization. However, efforts to connect protein sequences to the physical properties of condensates, that is, the molecular grammar, are hampered by a lack of effective approaches for probing high-resolution structural details. Using a combination of multiscale simulations and fluorescence lifetime imaging microscopy experiments, we systematically explored a series of systems consisting of diblock elastin-like polypeptides (ELPs). The simulations succeeded in reproducing the variation of condensate stability upon amino acid substitution and revealed different microenvironments within a single condensate, which we verified with environmentally sensitive fluorophores. The interspersion of hydrophilic and hydrophobic residues and a lack of secondary structure formation result in an interfacial environment, which explains both the strong correlation between ELP condensate stability and interfacial hydrophobicity scales, as well as the prevalence of protein-water hydrogen bonds. Our study uncovers new mechanisms for condensate stability and organization that may be broadly applicable.